Rietschel M. DFG - Deutsche Forschungsgemeinschaft SFB 636: TP Z04: Molecular Genetic core facility for genotype-phenotype delineation. 01/2012-12/2015.
As a core project Z03 will give methodological support to those studies within the SFB, that use diffusion
tensor imaging (DTI), functional magnetic resonance imaging (fMRI), including real-time fMRI, and
magnetic resonance spectroscopy (MRS) at 3.0T as well as advanced imaging and MRS methods at 9.4T.
Methods to directly compare functional connectivity and spatiotemporal dynamics acquired with BOLD and
regional cerebral blood volume (rCBV)-weighted fMRI in anesthetized rats at the 9.4T scanner will be
established. Various MRS editing techniques will be optimized for glutamine, GABA, glutathione, and
NAAG detection. Another goal of project Z03 is to combine structural connection maps determined by DTI
tractography and/or diffusion spectrum imaging (DSI) with brain network analysis of fMRI data to gain
insight into the patterning and dynamics of brain networks and to determine how structural connectivity
relates to functional and effective connectivity of the brain. Concepts from graph theory will be used to
analyze connection maps and brain network properties. These network properties such as clustering
coefficients, characteristic path length or global efficiency can then be quantified and translated to clinical
applications.
Rietschel M. EU - Europäische Union 279227: CRESTAR: Pharmacogenomic biomarkers as clinical decision making tools for clozapine treatment of schizophrenia. 11/2011-10/2015.
Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses, affecting about 1/3 of patients (~1 million Europeans), a considerable economic and social burden. First-line treatments include atypical (e.g. olanzapine) and typical (e.g. haloperidol) antipsychotics. The original atypical, clozapine, is a final option, and although it is the only antipsychotic shown to be effective in TRS, about half of TRS patients are also resistant to clozapine. CRESTAR is an SME-driven projected, focusing on the development of pharmacogenomic biomarkers for schizophrenia. It aims to develop tools to predict i) who will NOT respond to usual antipsychotics, indicating treatment with clozapine as early as possible, ii) the 1% of patients who will develop potentially fatal side effects, agranulocytosis, which is the main factor limiting clozapine use, and diabetic ketoacidosis, occurring in up to 2% of patients, and often fatal. We will also predict patients likely to be non-responders
to all antipsychotics, i.e. extreme TRS, so that they can be stratified in clinical trials. CRESTAR will address these questions by examining genome-wide association data, genome sequence, epigenetic biomarkers and epidemiological data in European patient cohorts characterized for treatment response, and adverse drug reaction using data from clozapine therapeutic drug monitoring and linked National population medical and pharmacy databases, alongside existing European projects (e.g. PSYCNVs and EU-GEI) national initiatives (e.g. UK10K genome sequencing) to identify predictive factors. In parallel CRESTAR will perform health economic research on potential benefits, and ethics and patient-centered research with stakeholders. The outcome of CRESTAR will be a genomic test and associated clinical decision making tools, designed to improve pharmacological treatment of schizophrenia in both efficacy and safety, piloted with existing and new clinical
trials such as OPTiMiSE.
Rietschel M. BMBF - Bundesministerium für Bildung und Forschung 01GS08147: NGFN Plus MooDS TP 5: Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophreniad: The MooDS Phenome Database and Reverse Phenotyping. 06/2011-05/2013.
Rietschel M, Rietschel M. EU - Europäische Union 224330 : ADAMS: Genomic variations underlying common neuropsychiatric diseases. 10/2009-12/2012.
The main objective of the ADAMS project is to promote the industrial exploitation and enhancement of the MARTE and other relevant standards for the development of real-time and embedded systems using both, model and component design paradigms.
The approach to achieve this objective is basically to promote and create a comunity around the technical solutions provided by these standards and feed-back their concerns into the standardization efforts. The project addresses in first person two very active industrial communities: the automotive and the avionics embedded systems development, and integration. This will be achieved by creating two corresponding groups of experts in the field, one for automotive and other for avionis, which despite their different bussines models, share the necessity of basic technologies for the validation and verification of the non-functional properties involved in the embedded systems life cycle.
Then, ADAMS will focus on promoting the usage of the OMG’s MARTE standard for MDD in both avionics and automotive domains. But at the same time capturing the concourse of the research comunity at large by promoting the visibility of MARTE in the various basic research forums that deal with the different aspects of the embedded distributed systems development.
Rietschel M, Rietschel M. EU - Europäische Union 224330 : ADAMS: Genomic variations underlying common neuropsychiatric diseases. 10/2009-12/2012.
The main objective of the ADAMS project is to promote the industrial exploitation and enhancement of the MARTE and other relevant standards for the development of real-time and embedded systems using both, model and component design paradigms.
The approach to achieve this objective is basically to promote and create a comunity around the technical solutions provided by these standards and feed-back their concerns into the standardization efforts. The project addresses in first person two very active industrial communities: the automotive and the avionics embedded systems development, and integration. This will be achieved by creating two corresponding groups of experts in the field, one for automotive and other for avionis, which despite their different bussines models, share the necessity of basic technologies for the validation and verification of the non-functional properties involved in the embedded systems life cycle.
Then, ADAMS will focus on promoting the usage of the OMG’s MARTE standard for MDD in both avionics and automotive domains. But at the same time capturing the concourse of the research comunity at large by promoting the visibility of MARTE in the various basic research forums that deal with the different aspects of the embedded distributed systems development.